AstraZeneca's Rare Drug Trial Failure Sends Shares Plunging

AstraZeneca's stock fell more than 10% after the company announced that a trial of its experimental heart drug did not meet its primary endpoint in preventing heart problems among patients with a rare disease. Bloomberg reported the development on its "Bloomberg Open Interest" program. The drug's clinical trial results were disclosed by the pharmaceutical company.

Next story